Replimune Group (REPL) News
NASDAQ: REPLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
19.07-0.16 (-0.83%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
REPL news summary
We found 14 recent headlines mentioning Replimune Group (REPL): 0 in the past week and 11 in the past 30 days, most often from Nasdaq, Seeking Alpha, GlobeNewswire. For price context, REPL is down 0.83% at $19.07. The most recent story, "REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress", was published by Nasdaq on Nov 12, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Replimune Group headlines
- REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline ProgressReplimune shares surge 80% as Tudriqev's commercial launch gains traction, earnings beat expectations and pipeline progress strengthens growth prospects.NasdaqREPL, BMY, ADPT, ACIU
- Replimune Group Consensus Price Target Increased by 14.78% to $22.44The average one-year price target for Replimune Group (NASDAQGS:REPL) (DB:7R8) has been revised to $22.44 / share. This is an increase of 14.78% from the prior estimate of $19.55 dated October 20,…NasdaqREPL, LEN.B
- Replimune: 3 Key Takeaways for Long-Term InvestorsKey PointsReplimune ended the second quarter with $307.8 million in cash.Nasdaq
- Replimune (REPL) Q2 2027 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Replimune anticipates permanent J-code by April 2027 as TUDRIQEV launch metrics buildSeeking Alpha
- Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%(RTTNews) - Shares of several biotech companies moved higher following quarterly financial results, clinical trial developments and business updates. Genmab reported positive Phase 3 results for its…NasdaqAXGN, GMAB, KIDS, LUNG
- Replimune Group, Inc. Reports Fiscal Second Quarter 2027 Financial Results and TUDRIQEV LaunchReplimune Group, Inc. announced its financial results for the fiscal second quarter ended September 30, 2026, and provided a corporate update. The company highlighted the commercial launch of…Nasdaq
- Replimune Posts Narrower Loss In Q2(RTTNews) - Replimune Group, Inc. (REPL) on Wednesday reported a narrower loss in the second quarter due to a decline in operating expenses. The company also provided several clinical and business…NasdaqREPL, HEI.A
- Replimune Group GAAP EPS of -$0.54 beats by $0.21Seeking Alpha
- Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate UpdateTUDRIQEV first delivered to patients for advanced melanoma on October 6thGlobeNewswire
- Notable Tuesday Option Activity: MCY, INSM, REPLAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Mercury General Corp. (Symbol: MCY), where a total of 2,961 contracts have traded so far,…NasdaqMCY, INSM, REPL
- Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today…GlobeNewswire
- New FDA Drug Approvals - August 2026(RTTNews) - The U.S. Food and Drug Administration (FDA) granted approval to 13 drugs last month, comprising both new drug approvals and expanded indications for previously approved therapies.NasdaqBMY, BNTX, GILD, JAZZ
- Noteworthy Tuesday Option Activity: REPL, SLS, COKELooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Replimune Group Inc (Symbol: REPL), where a total volume of 32,320 contracts has…NasdaqREPL, SLS, COKE